Related Experiment Video
Updated: Mar 24, 2026
Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
Published on: January 12, 2024
FTY720 Attenuates Retinal Inflammation and Protects Blood-Retinal Barrier in Diabetic Rats
Purpose:
FTY720 has shown a protective effect in several diseases via inhibiting inflammation and decreasing vascular permeability. The purpose of this study was to assess the impact of FTY720 on inflammation and the blood-retinal barrier (BRB) in diabetic rats.
Methods:
Male Wister rats were induced to develop diabetes by streptozotocin, and FTY720 was administered by oral gavage daily for 12 weeks. All experiments were performed at 12 weeks after model establishment. Gene expression was assessed by real-time PCR. Protein expression and/or distribution were assessed by Western blotting and/or immunohistochemistry. The BRB breakdown was determined by staining of retinal whole mounts and quantified using Evans blue.
Results:
FTY720 induced lymphopenia in diabetic rats. Proinflammatory cytokines (TNF-α, IL-6, and IL-1β) and adhesion molecules (inter-cellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) were increased in retinas of diabetic rats. FTY720 significantly inhibited the up-regulation of these inflammatory factors. FTY720 also suppressed nuclear factor-κB activation seen in retinas of diabetic rats. Additionally, FTY720 prevented BRB breakdown and reduction of tight junction proteins (ZO-1, Occludin, and Claudin-5) in the retinas of diabetic rats. Down-regulation of S1P1 and S1P3 was also reversed by FTY720 in retinas of diabetic rats.
Conclusions:
FTY720 provides protection against diabetic retinopathy (DR), which may involve its anti-inflammatory and barrier-enhancing effects. The S1PR modulation may serve as a novel approach to treat patients with DR.
Insights
FTY720 treatment protected against diabetic retinopathy in rats by reducing inflammation and preserving the blood-retinal barrier. This suggests sphingosine-1-phosphate receptor modulation is a potential therapeutic strategy for diabetic eye disease.
Area of Science:
- Ophthalmology
- Pharmacology
- Immunology
Background:
- Diabetic retinopathy (DR) is a leading cause of blindness.
- Inflammation and blood-retinal barrier (BRB) breakdown are key pathological features of DR.
- FTY720 (fingolimod) is known to modulate immune responses and vascular permeability.
Purpose of the Study:
- To investigate the therapeutic potential of FTY720 in a rat model of diabetic retinopathy.
- To assess the effects of FTY720 on retinal inflammation and BRB integrity in diabetic rats.
Main Methods:
- Diabetes was induced in Wistar rats using streptozotocin.
- FTY720 was administered orally daily for 12 weeks.
- Retinal gene and protein expression, inflammation markers, nuclear factor-κB activation, BRB integrity (Evans blue staining), and tight junction proteins were analyzed.
Main Results:
- FTY720 reduced proinflammatory cytokines (TNF-α, IL-6, IL-1β) and adhesion molecules in diabetic rat retinas.
- FTY720 suppressed nuclear factor-κB activation and prevented BRB breakdown.
- FTY720 restored levels of tight junction proteins (ZO-1, Occludin, Claudin-5) and reversed S1P receptor downregulation.
Conclusions:
- FTY720 demonstrates protective effects against diabetic retinopathy in rats.
- These benefits are attributed to FTY720's anti-inflammatory actions and its ability to enhance BRB integrity.
- Modulation of sphingosine-1-phosphate receptors (S1PR) by FTY720 presents a novel therapeutic avenue for DR treatment.
